Artificial intelligence in antibodies & vaccines development

The advent of artificial intelligence (AI) has opened new opportunities for vaccine and antibody development. AI-driven approaches have for example the potential to rapidly advance the identification of immunogens and novel adjuvant candidates with optimal safety and efficacy profiles. To provide more insights into the transformative impact of AI on translation and product development driven activities, the Bridging Topics “Vaccines” and “Antibody-based Therapies” organize a joint Bridging Topic workshop.

Click here to learn more about the conference.